Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysis
- 1 March 2011
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 10 (1), 63-69
- https://doi.org/10.3816/ccc.2011.n.009
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Molecular Basis of Colorectal CancerThe New England Journal of Medicine, 2009
- KRAS Mutation Testing in Colorectal CancerAdvances in Anatomic Pathology, 2009
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion QuestionJNCI Journal of the National Cancer Institute, 2009
- Provisional Clinical OpinionJournal of Clinical Oncology, 2009
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody TherapyJournal of Clinical Oncology, 2009
- Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With CetuximabJournal of Clinical Oncology, 2007
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and FluoropyrimidinesJournal of Clinical Oncology, 2006
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal CancerCancer Research, 2006
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004